(1)
TOKYO, Mar 5, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that the latest data from its Alzheimer s disease (AD) and dementia pipeline, including the investigational anti-amyloid beta (Aß) protofibril antibody lecanemab (Development Code: BAN2401), will be presented at the 15th International Conference on Alzheimer s and Parkinson s Disease (AD/PD2021) to be held virtually from March 9 to 14, 2021.
Regarding lecanemab, preliminary analysis results of changes in brain-Aß amounts as observed in subjects of the ongoing open-label extension (OLE) of the Phase II study (Study 201) will be presented orally.
Regarding aducanumab, for which applications are currently underway in the U.S., Europe and Japan, Biogen Inc. will conduct presentations on the correlation of amyloid PET and cerebrospinal fluid (CSF) biomarkers in the Phase III studies (EMERGE/ENGAGE), as well as evaluations of the safety and efficacy of aducanumab in early AD. Lecanemab and aducanumab are being j
IMMERSIVE MINDFULNESS PLATFORM LAUNCHES
Estonia-born MindSpa app, Synctuition has partnered up with haptic sound technology company, Woojer, to create an immersive mindfulness experience for its users.
Synctuition s platform uses 3D sounds recorded in over 2000 locations allowing for accurate replication of those environments. This creates something called environmental psychology, helping its listeners achieve deep relaxation by feeling like they are in these natural dreamscapes.
Co-founder of Synctuition Michael Burich said: “For a long time, we looked at the potential crossover of the mindfulness and gaming worlds, and this is our first of many steps into gaming. When paired with the spectacular audio journeys of Synctuition, we came up with what we feel is almost a new category of entertainment. That’s why this partnership made so much sense.”
LSP and Philip Scheltens launch new, unique fund to fight dementia
News provided by
Share this article
Share this article
AMSTERDAM, Jan. 12, 2021 /PRNewswire/ LSP, the leading European life sciences investor, today announces the launch of the LSP Dementia Fund, a fund dedicated to fight neurodegenerative diseases. The fund will be managed by Professor Philip Scheltens, a world-renowned dementia scientist and thought leader.
Dementia is the greatest healthcare challenge of our time. A staggering 50 million patients suffer from dementia worldwide and predicted to triple to 150 million before the year 2050. The burden to our healthcare system is equally large; global costs are currently estimated to amount to over $800 billion - or 1.1% of global GDP - and will rise exponentially if no treatment is found. Yet, investments in R&D to find novel treatments are lagging behind.